Novavax INC

Novavax reported a significant decrease in first-quarter 2026 revenue, largely due to the prior year's non-cash sales, but highlighted substantial growth in strategic partnerships and licensing agreements.

Novavax reported a significant financial turnaround in 2025, achieving net income and securing a major licensing agreement with Pfizer for its Matrix-M adjuvant.

Novavax, Inc. entered into a License and Option Agreement with Pfizer Inc. for its Matrix-M™ adjuvant technology, potentially generating over $530 million in upfront and milestone payments plus royalties.

Novavax details a strategic transformation at J.P. Morgan, focusing on partnerships, R&D innovation, and a path to non-GAAP profitability by 2028, alongside preliminary 2025 financial insights.

Novavax reports third-quarter 2025 financial results, highlighting strong Sanofi partnership milestones, significant cost savings from Maryland site consolidation, and an increased full-year revenue framework.

Novavax completed the transfer of U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi, triggering a $25 million milestone payment.

Novavax reported a significant revenue decline in Q1 2026, primarily due to lower product sales, but saw a substantial increase in licensing, royalties, and other income, driven by new partnerships and amortization of upfront payments.

Novavax reports a significant increase in nine-month revenue driven by APA terminations and Sanofi collaboration milestones, alongside a Q3 net loss and strategic debt refinancing.

Novavax reported a significant net income increase for the first half of 2025 driven by contract terminations, despite a Q2 revenue decline, as it advances key partnerships and pipeline assets.

Novavax reports a significant turnaround in Q1 2025, posting a net income of $518.6 million, primarily due to revenue from collaboration agreements and termination of Advance Purchase Agreements (APAs).

Novavax's Q3 2024 results show a decrease in revenue primarily due to reduced government grants, offset by increased product sales and licensing revenue from the Sanofi partnership.

Novavax's Q2 2024 results show a significant increase in revenue driven by a licensing agreement with Sanofi, alongside a reduction in operating expenses.

Novavax reported a significant financial turnaround in 2025, achieving net income of $440.3 million, driven by strategic partnership milestones and cost reductions, while securing new collaborations for its Matrix-M adjuvant.

Novavax's 2024 10-K filing details financial results, strategic shifts including a major Sanofi partnership, and ongoing development of its vaccine pipeline.

Novavax's 10-K filing details the company's common stock, preferred stock, and various corporate governance provisions as of December 31, 2023.

Novavax Director Charles W. Newton acquired 9,520 shares of common stock through the vesting of restricted stock units.

Novavax EVP of R&D Robert Walker was granted 99,500 stock options and 66,000 restricted stock units on April 14, 2026.

Novavax's EVP, CFO, and Treasurer, James Patrick Kelly, reported the vesting of 43,167 Restricted Stock Units and a subsequent sale of 20,850 shares to cover tax obligations.

Novavax President and CEO, John C. Jacobs, reported the vesting of 150,167 Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Novavax's Chief Strategy Officer, Elaine O'Hara, acquired common stock through RSU vesting and sold shares for tax obligations, increasing her direct beneficial ownership.

Novavax's EVP, Chief Legal Officer, Mark J. Casey, increased his direct common stock ownership by 26,122 shares after RSU vesting and tax withholding, with an additional 4,000 RSUs vesting.

Novavax, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 18, 2026, with key proposals including director elections and stock plan amendments.

Novavax has scheduled its annual stockholder meeting for June 20, 2025, and is seeking votes on director elections, executive compensation, and auditor ratification.

Novavax's 2025 proxy statement outlines a strategic shift towards maximizing its technology platform through partnerships and pipeline expansion, moving beyond COVID-19 vaccine commercialization.

Novavax amends its definitive proxy statement to clarify non-employee director compensation limits under the Amended 2015 Stock Incentive Plan.

Novavax has filed its definitive proxy statement with the SEC, outlining details for its upcoming shareholder meeting.

Novavax has scheduled its 2024 Annual Meeting of Stockholders for June 13, 2024, featuring proposals ranging from director elections to executive compensation and stock plan amendments.

Shah Capital Management has submitted an amendment to its Schedule 13D filing, criticizing Novavax's current leadership and outlining perceived failures in marketing, partnerships, capital management, and executive compensation.

Shah Capital Management, a significant shareholder, has announced its intention to vote against Novavax's board nominees and executive compensation, citing value destruction and operational failures.

Shah Capital, an 8.3% shareholder, publicly criticized Novavax's management for operational failures, high costs, and poor vaccine rollout, urging the board to seek a sale to a larger pharma company.

Activist investor Shah Capital, holding 7.3% of Novavax, demands an immediate strategic review and potential sale of the company, citing persistent underperformance and operational failures.

Vanguard Capital Management has reported beneficial ownership of over 8.3 million shares, representing 5.09% of Novavax Inc.'s common stock.

Bank of America Corporation has reported a 4.1% beneficial ownership in Novavax Inc. common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Novavax Inc. common stock following an internal realignment.

Bank of America Corporation and its subsidiaries have reported a 5.1% beneficial ownership stake in Novavax Inc. common stock.

State Street Corporation has reported a 5.9% beneficial ownership stake in Novavax Inc., holding over 9.5 million shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.4% of Novavax Inc.'s common stock as of December 31, 2024.